Jefferies upgrades Oscar Health stock rating on pricing outlook

Jefferies upgraded Oscar Health to Hold from Underperform and lifted its price target to $16 from $10, citing improving 2026 bid pricing and market enrollment trends. The firm now expects 2026 margins roughly in line with guidance and raised its 2027 EPS estimate to $1.31 from $0.38, though it trimmed margin expansion assumptions to about 100 bps from 210 bps. Oscar also recently missed Q4 2025 estimates, posting EPS of -$1.24 versus -$0.89 expected and revenue of $2.81 billion versus $3.11 billion.

Analysis

The upgrade matters less for the near-term multiple and more for what it implies about the quality of Oscar’s growth. If the company is indeed capturing disproportionately better exchange risk, the market may be underestimating how much of 2026 earnings power is already visible in enrollment mix rather than just headline membership growth. That creates a second-order winner set: reinsurers and peers with weaker underwriting discipline could face a margin-compression problem if OSCR proves that selective growth is still available in a tightening market.

The key risk is that this is a “good news now, bad news later” setup. Health exchange economics can look stable for several quarters before morbidity leakage shows up, and the biggest reversal trigger is not a slow drift but a policy shock that changes the risk pool quickly. Any combination of subsidy normalization, payment rule tightening, or a deterioration in cost-sharing support would hurt the marginal member quality first, then show up with a lag in 2027 medical costs and risk adjustment.

Consensus appears to be treating the upgrade as a confirmation of a durable rerating, but the implied valuation already bakes in a fairly clean execution path. The market is assigning a premium to margin recovery, yet the real debate is whether 2027 can keep compounding once the easy share gains are harvested. If the stock is pricing a transition from “survival” to “quality growth,” the upside is still there, but the asymmetry now favors those who can monetize the rerating while keeping downside hedged.

For trading, this is better expressed as a tactical long rather than a blind long-duration compounder. The most attractive setup is into any post-earnings or post-upgrade pullback toward the mid-teens, with a defined stop if management commentary turns cautious on 2027 margin expansion. The upside case is a continued multiple lift on proof of underwriting discipline; the downside case is that the stock becomes range-bound once investors realize earnings inflection is already largely in the price.

Key Decisions for Investors

• Buy OSCR on a pullback into the $14.50-$15.00 area over the next 1-3 weeks; target $18-$19 on confirmation that 2026 margin is tracking guidance, with a stop below $13.50 if enrollment/morbidity commentary weakens.
• Use a call spread in OSCR for event-driven upside: buy the 6-9 month $16/$20 call spread to capture rerating while limiting downside if the stock stalls near the current target zone.
• Pair trade: long OSCR / short a higher-beta ACA-exchange peer with weaker underwriting credibility for 3-6 months; the relative value is that OSCR can outperform if the market rewards visible risk selection while punishing less disciplined growth.
• Trim into strength above the new $16 target if 2027 guidance does not improve materially; the stock can stay elevated, but the incremental upside from here is likely smaller than the downside from any morbidity surprise.